Humana Inc. (HUM) gains on deep earnings beat analysis
Humana Inc. (HUM) gained after a better-than-feared Q3 earnings beat, but the real story is the deeper recovery setup. Revenue improved sequentially, guidance rose, and management pointed to easing medical cost trends, stronger membership growth, and a clearer path to margin recovery.
Humana Inc. (HUM) posted a better-than-feared third quarter, with adjusted EPS of -$0.70 versus the -$1.00 consensus and revenue of $41.16 billion above estimates. The company also raised its 2026 adjusted EPS outlook to at least $9.50, signaling a firmer recovery path as medical cost trends improve and membership growth accelerates in key businesses. Investors viewed the print as a constructive step toward margin recovery, even though earnings remain volatile and the turnaround is still in progress.
Humana Inc. (HUM) delivered a better-than-feared third quarter: adjusted EPS came in at -$0.70 versus the -$1.00 consensus estimate, while revenue reached $41.16B against $40.87B expected. HUM shares gained 3.82% to $427.50 in regular trading on Nov. 6, with 1,496,089 shares traded versus an average of 1,244,321, as the market absorbed higher guidance and a firmer recovery path.
Key Takeaways
HUM earnings beat both major estimates. Adjusted EPS was -$0.70 versus -$1.00 expected, while revenue was $41.16B versus $40.87B.
Revenue continued to build sequentially, rising from $39.65B in Q1 and $40.87B in Q2 to $41.16B in Q3.
Humana raised its 2026 adjusted EPS outlook to at least $9.50 from at least $9.00.
Management reported a 4.17 member-weighted Stars rating for BY28 and expects a one-time 2028 tailwind, with some funds directed to investment and shareholder returns.
CenterWell Primary Care added nearly 147,000 members, or 30% growth, while Medicaid membership increased by 104,000 in 2026.
Analyst sentiment remains mixed but constructive. The consensus rating is Hold, while Jefferies reiterated Buy with a $420 price target after the quarter.
Financial Performance: Revenue Growth and the EPS Bridge
The central HUM earnings result was a revenue beat paired with a smaller-than-expected loss. Revenue reached $41.16B, compared with $40.87B in Q2, $39.65B in Q1, $32.52B in Q4 2025, and $32.65B in the year-earlier quarter. The sequential increase gives the business a stronger top-line base as management works through Medicare Advantage margin pressure.
Profitability remained uneven. The quarterly financial series lists net income of $0.16B in Q3, down from $0.69B in Q2 and $1.19B in Q1. The same series lists EPS of $1.35 in Q3, $5.79 in Q2, $9.85 in Q1, -$6.61 in Q4 2025, and $1.62 in Q3 2025. Those figures differ from the -$0.70 adjusted EPS headline because Humana distinguishes GAAP and non-GAAP measures on its earnings call.
The earnings surprise history also shows why a single-quarter beat does not equal a normalized earnings profile. Actual EPS was $7.61 in Q2, $10.31 in Q1, -$3.96 in Q4 2025, and $3.24 in Q3 2025. The latest result improved against the -$1.00 estimate, but the wide quarterly swings keep the recovery story firmly tied to cost control and Medicare Advantage execution.
Humana's annual segment data shows the scale of its two main engines. Insurance Segment revenue reached $124.563B in 2025, up from $113.764B in 2024. CenterWell Segment revenue reached $22.473B, compared with $19.936B in 2024. Insurance remains the profit engine, while CenterWell provides a growing care-delivery platform that management is expanding through primary care and value-based models.
Cost trends supplied the more important margin signal. CFO Celeste Mellet said 2026 medical cost trend was running at the lower end of the 7% to 8% range. She cited better inpatient performance, including admissions and cost per admission, plus favorable Part D results. For 2027, the company expects trend to rise to 8% to 9%, with Part D trend at 14% to 15% because of the health technology pipeline.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
The regular-session market response was positive. HUM traded at $427.50, up 3.82%, while volume reached 1,496,089 shares versus an average of 1,244,321. That combination points to active buying after the EPS beat, the revenue beat, and the higher full-year outlook.
The broader analyst mix remains cautious. Consensus includes 21 Buy ratings, 22 Hold ratings, and one Sell rating, producing an overall Hold view. Jefferies provided the clearest immediate endorsement by reiterating Buy and keeping its $420 price target. Analyst David Windley said the Insurance Medical Loss Ratio came in about 40 basis points better than management guidance and maintained that the quarter supports meaningful 2027 margin recovery and a 3% Individual Medicare Advantage margin in 2028.
Several firms had already improved their stance before the quarter. Raymond James upgraded HUM to Outperform from Market Perform with a $520 target. Truist raised its target to $475 from $415 while keeping Hold. UBS raised its target to $495 from $405 with a Neutral rating, and Oppenheimer raised its target to $525 from $475 while keeping Outperform. Those actions created a constructive baseline before the new results arrived.
The quarter should not change our view for meaningful 2027 margin recovery and a 3% Individual Medicare Advantage margin in 2028.
- David Windley, Jefferies
Management Commentary: A Recovery Plan With Milestones
We have just one headline today, and that is that we are in a good place.
- James Rechtin, CEO, Earnings Call
CEO James Rechtin framed the quarter as evidence that Humana's strategy is moving from plan toward ahead of plan. He pointed to four operating drivers: product experience, clinical results, efficient operations, and capital allocation. Annual enrollment performance is ahead of initial expectations, planned-exit member retention is strong, and new sales are ahead of plan. Management currently expects 2027 membership to increase.
The strongest strategic data point was the BY28 Stars result. Humana reached a 4.17 member-weighted rating, which exceeded its top-quartile goal. Rechtin said the company expects a one-time tailwind in 2028, then plans to use part of it to strengthen Stars capabilities and improve customer experience. He also expects a portion to flow to shareholders.
Our performance to date supports an increase in our full year adjusted EPS outlook from at least $9 to at least $9.50.
- Celeste Mellet, CFO, Earnings Call
Mellet supplied the financial bridge. She said cost trends were in line with or better than expectations, reserves continued to build, and Humana remained on track to double its individual Medicare Advantage pretax margin in 2026, excluding the Stars headwind.
Balance-sheet efficiency also improved. Humana expects roughly $900M in pretax proceeds from its Gentiva minority-interest divestment. The new BlackRock joint venture is expected to reduce GAAP debt-to-capital by about 130 basis points in Q4. It also removes the need to fund a 2027 put option that otherwise would have increased debt-to-capital by about 130 basis points.
Wells Fargo analyst Stephen Baxter pressed management on the 2027 bridge, including possible headwinds, tailwinds, and the expected improvement in individual Medicare Advantage margins.
I was hoping you could expand a little bit more on the 2027 commentary, maybe a potential list of headwinds and tailwinds.
- Stephen Baxter, Wells Fargo
We don't have any known headwinds other than carrying the Stars headwind we have from this year.
- Celeste Mellet, CFO, Earnings Call
Mellet listed operating transformation, Medicaid and primary-care J-curves, improved product pricing, and fewer new members as the main tailwinds. She declined to set a precise 2027 margin endpoint because membership size and mix remain tied to annual enrollment results. Still, she described improvement as material on both Stars-adjusted and unadjusted bases.
Wolfe Research analyst Justin Lake pushed on two pressure points: medical cost trends and a material year-over-year decline in one CenterWell area.
The year-over-year decline was pretty material, and you talked about one specific market and group of patients being pressured.
- Justin Lake, Wolfe Research
We're at the lower end of the range that we had expected for the year, which was 7% to 8%.
- Celeste Mellet, CFO, Earnings Call
Mellet focused her response on inpatient performance, value-based providers, and Part D favorability. The exchange reinforced the central tradeoff in the Humana Inc. earnings analysis: insurance cost control is improving, while CenterWell still contains pockets of operating pressure.
Bottom Line
HUM earnings showed better near-term execution, a raised 2026 EPS floor, strong Stars performance, and a clearer path toward 2027 margin recovery and a 3% plus Medicare Advantage margin in 2028. The volatile EPS history still demands discipline, but the combination of cost control, membership growth, and balance-sheet progress gives Humana a more credible recovery case than it had earlier in 2026.
Yes. Humana reported adjusted EPS of -$0.70, better than the -$1.00 consensus estimate, and revenue of $41.16 billion versus $40.87 billion expected.
+Why did Humana stock rise after the Q3 earnings report?
HUM shares rose 3.82% to $427.50 because the company beat both EPS and revenue estimates and raised its 2026 adjusted EPS outlook to at least $9.50. Investors also reacted positively to improving medical cost trends and management's more confident recovery outlook.
+What did Humana say about its 2026 earnings guidance?
Humana raised its 2026 adjusted EPS outlook to at least $9.50 from at least $9.00. That higher guide suggests management sees a stronger path to profitability as costs stabilize and operations improve.
+What were the key operational trends in Humana's quarter?
CenterWell Primary Care added nearly 147,000 members, representing 30% growth, and Medicaid membership increased by 104,000 in 2026. Management also said the 2026 medical cost trend was running at the lower end of the 7% to 8% range, which supports margin recovery.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on HUM?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.